Targeting interleukin-6 for noninfectious uveitis

References

• KornTMitsdoerfferMCroxfordALIL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cellsProc Natl Acad Sci U S A200810547184601846519015529
   PubMed Web of Science ®Google Scholar
• TanakaTNarazakiMKishimotoTIL-6 in inflammation, immunity, and diseaseCold Spring Harb Perspect Biol2014610a01629525190079
   PubMed Web of Science ®Google Scholar
• OkadaMKitaharaMKishimotoSMatsudaTHiranoTKishimotoTIL-6/BSF-2 functions as a killer helper factor in the in vitro induction of cytotoxic T cellsJ Immunol19881415154315493261754
   PubMed Web of Science ®Google Scholar
• BettelliECarrierYGaoWReciprocal developmental pathways for the generation of pathogenic effector TH17 and regulatory T cellsNature2006441709023523816648838
   PubMed Web of Science ®Google Scholar
• VoorheesPMChenQSmallGWTargeted inhibition of interleukin-6 with CNTO 328 sensitizes pre-clinical models of multiple myeloma to dexamethasone-mediated cell deathBr J Haematol2009145448149019344406
   PubMed Web of Science ®Google Scholar
• Ataie-KachoiePPourgholamiMHMorrisDLInhibition of the IL-6 signaling pathway: a strategy to combat chronic inflammatory diseases and cancerCytokine Growth Factor Rev201324216317323107589
   PubMed Web of Science ®Google Scholar
• YamasakiKTagaTHirataYCloning and expression of the human interleukin-6 (BSF-2/IFN beta 2) receptorScience198824148678258283136546
   PubMed Web of Science ®Google Scholar
• TanakaTNarazakiMOgataAKishimotoTA new era for the treatment of inflammatory autoimmune diseases by interleukin-6 blockade strategySemin Immunol2014261889624594001
   PubMed Web of Science ®Google Scholar
• KimNHLeeMYParkSJChoiJSOhMKKimISAuranofin blocks interleukin-6 signalling by inhibiting phosphorylation of JAK1 and STAT3Immunology2007122460761417645497
   PubMed Web of Science ®Google Scholar
• HeinrichPCCastellJVAndusTInterleukin-6 and the acute phase responseBiochem J199026536216361689567
   PubMed Web of Science ®Google Scholar
• NemethERiveraSGabayanVIL-6 mediates hypoferremia of inflammation by inducing the synthesis of the iron regulatory hormone hepcidinJ Clin Invest200411391271127615124018
   PubMed Web of Science ®Google Scholar
• TzengHETsaiCHChangZLInterleukin-6 induces vascular endothelial growth factor expression and promotes angiogenesis through apoptosis signal-regulating kinase 1 in human osteosarcomaBiochem Pharmacol201385453154023219526
   PubMed Web of Science ®Google Scholar
• MayaJRSadiqMAZapataLJEmerging therapies for noninfectious uveitis: what may be coming to the clinicsJ Ophthalmol2014201431032924868451
   PubMed Web of Science ®Google Scholar
• YoshimuraTSonodaKHOhguroNInvolvement of Th17 cells and the effect of anti-IL-6 therapy in autoimmune uveitisRheumatology200948434735419164426
   PubMed Web of Science ®Google Scholar
• MesquidaMLeszczynskaALlorencVAdanAInterleukin-6 blockade in ocular inflammatory diseasesClin Exp Immunol2014176330130924528300
   PubMed Web of Science ®Google Scholar
• PerezVLPapaliodisGNChuDAnzaarFChristenWFosterCSElevated levels of interleukin 6 in the vitreous fluid of patients with pars planitis and posterior uveitis: the Massachusetts eye and ear experience and review of previous studiesOcul Immunol Inflamm200412319320115385196
   PubMed Web of Science ®Google Scholar
• MurrayPIHoekzemaRvan HarenMAde HonFDKijlstraAAqueous humor interleukin-6 levels in uveitisInvest Ophthalmol Vis Sci19903159179202335453
   PubMed Web of Science ®Google Scholar
• KramerMMonseliseYBaharICohenYWeinbergerDGoldenberg-CohenNSerum cytokine levels in active uveitis and remissionCurr Eye Res2007327–866967517852191
   PubMed Web of Science ®Google Scholar
• HiranoTMatsudaTTurnerMExcessive production of interleukin 6/B cell stimulatory factor-2 in rheumatoid arthritisEur J Immunol19881811179718012462501
   PubMed Web of Science ®Google Scholar
• StuartRALittlewoodAJMaddisonPJHallNDElevated serum interleukin-6 levels associated with active disease in systemic connective tissue disordersClin Exp Rheumatol199513117227774098
   PubMed Web of Science ®Google Scholar
• OshitariTKajitaFTobeARefractory uveitis in patient with castleman disease successfully treated with tocilizumabCase Rep Ophthalmol Med2012201296818023198204
   PubMedGoogle Scholar
• Kaminiarczyk-PyzalkaDAdamczakKMikosHKlimeckaIMoczkoJNiedzielaMProinflammatory cytokines in monitoring the course of disease and effectiveness of treatment with etanercept (ETN) of children with oligo- and polyarticular juvenile idiopathic arthritis (JIA)Clin Lab20146091481149025291944
   PubMed Web of Science ®Google Scholar
• SpirchezMSamascaGIancuMBolbaCMiuNRelation of interleukin-6, TNF-alpha and interleukin-1alpha with disease activity and severity in juvenile idiopathic arthritis patientsClin Lab2012583–425326022582498
   PubMed Web of Science ®Google Scholar
• TappeinerCHeinzCGanserGHeiligenhausAIs tocilizumab an effective option for treatment of refractory uveitis associated with juvenile idiopathic arthritis?J Rheumatol20123961294129522661419
   PubMed Web of Science ®Google Scholar
• TsangACRothJGottliebCTocilizumab for severe chronic anterior uveitis associated with juvenile idiopathic arthritis in a pediatric patientOcul Immunol Inflamm201422215515724377416
   PubMed Web of Science ®Google Scholar
• AdanAMesquidaMLlorencVTocilizumab treatment for refractory uveitis-related cystoid macular edemaGraefes Arch Clin Exp Ophthalmol2013251112627263223893042
   PubMed Web of Science ®Google Scholar
• MesquidaMMolinsBLlorencVSainz de la MazaMAdanALong-term effects of tocilizumab therapy for refractory uveitis-related macular edemaOphthalmology2014121122380238625204610
   PubMed Web of Science ®Google Scholar
• PapoMBielefeldPValletHTocilizumab in severe and refractory non-infectious uveitisClin Exp Rheumatol2014324 Suppl 84S75S7925268663
   PubMed Web of Science ®Google Scholar
• TanakaYMartin MolaEIL-6 targeting compared to TNF targeting in rheumatoid arthritis: studies of olokizumab, sarilumab and sirukumabAnn Rheum Dis20147391595159724833786
   PubMed Web of Science ®Google Scholar
• SmolenJSWeinblattMEShengSZhuangYHsuBSirukumab, a human anti-interleukin-6 monoclonal antibody: a randomised, 2-part (proof-of-concept and dose-finding), phase II study in patients with active rheumatoid arthritis despite methotrexate therapyAnn Rheum Dis20147391616162524699939
   PubMed Web of Science ®Google Scholar
• HuizingaTWFleischmannRMJassonMSarilumab, a fully human monoclonal antibody against IL-6Ralpha in patients with rheumatoid arthritis and an inadequate response to methotrexate: efficacy and safety results from the randomised SARIL-RA-MOBILITY Part A trialAnn Rheum Dis20147391626163424297381
   PubMed Web of Science ®Google Scholar
• GenoveseMCFleischmannRFurstDEfficacy and safety of olokizumab in patients with rheumatoid arthritis with an inadequate response to TNF inhibitor therapy: outcomes of a randomised Phase IIb studyAnn Rheum Dis20147391607161524641941
   PubMed Web of Science ®Google Scholar
• MeasePStrandVShalamberidzeLA phase II, double-blind, randomised, placebo-controlled study of BMS945429 (ALD518) in patients with rheumatoid arthritis with an inadequate response to methotrexateAnn Rheum Dis20127171183118922328739
   PubMed Web of Science ®Google Scholar
• KurzrockRVoorheesPMCasperCA phase I, open-label study of siltuximab, an anti-IL-6 monoclonal antibody, in patients with B-cell non-Hodgkin lymphoma, multiple myeloma, or Castleman diseaseClin Cancer Res201319133659367023659971
   PubMed Web of Science ®Google Scholar
• El-AsrarAMStruyfSKangaveDCytokine profiles in aqueous humor of patients with different clinical entities of endogenous uveitisClin Immunol2011139217718421334264
   PubMed Web of Science ®Google Scholar
• Montero-JulianFAThe soluble IL-6 receptors: serum levels and biological functionCell Mol Biol200147458359711502067
   PubMed Web of Science ®Google Scholar
• MuangchantCPopeJEThe significance of interleukin-6 and C-reactive protein in systemic sclerosis: a systematic literature reviewClin Exp Rheumatol2013312 Suppl 7612213423910616
   PubMed Web of Science ®Google Scholar
• PignattiPCiapponiLGallePHigh circulating levels of biologically inactive IL-6/SIL-6 receptor complexes in systemic juvenile idiopathic arthritis: evidence for serum factors interfering with the binding to gp130Clin Exp Immunol2003131235536312562400
   PubMed Web of Science ®Google Scholar
• ShimamotoKItoTOzakiYSerum interleukin 6 before and after therapy with tocilizumab is a principal biomarker in patients with rheumatoid arthritisJ Rheumatol20134071074108123637318
   PubMed Web of Science ®Google Scholar
• BorgesAHO’ConnorJLPhillipsANFactors associated with plasma IL-6 levels during HIV infectionJ Infect Dis Epub2262015
   Web of Science ®Google Scholar
• LykeKEBurgesRCissokoYSerum levels of the proinflammatory cytokines interleukin-1 beta (IL-1beta), IL-6, IL-8, IL-10, tumor necrosis factor alpha, and IL-12(p70) in Malian children with severe Plasmodium falciparum malaria and matched uncomplicated malaria or healthy controlsInfect Immun200472105630563715385460
   PubMed Web of Science ®Google Scholar
• ZhouYHoriuchiSYamamotoMYamamotoNElevated serum levels of the soluble form of gp130, the IL-6 signal transducer, in HTLV-1 infection and no involvement of alternative splicing for its generationMicrobiol Immunol19984221091169572042
   PubMed Web of Science ®Google Scholar
• ChiNTanZMaKBaoLYunZIncreased circulating myeloid-derived suppressor cells correlate with cancer stages, interleukin-8 and -6 in prostate cancerInt J Clin Exp Med20147103181319225419348
   PubMed Web of Science ®Google Scholar
• LuCCKuoHCWangFSJouMHLeeKCChuangJHUpregulation of TLRs and IL-6 as a marker in human colorectal cancerInt J Mol Sci201516115917725547486
   PubMed Web of Science ®Google Scholar
• MarkkulaASimonssonMIngvarCRoseCJernstromHIL6 genotype, tumour ER-status, and treatment predicted disease-free survival in a prospective breast cancer cohortBMC Cancer20141475925305747
   PubMed Web of Science ®Google Scholar
• NeematKRaniaKTarekMHamdyAAEffect of 13q deletion on IL-6 production in patients with multiple myeloma: a hypothesis may hold trueClin Lab20146081393139925185427
   PubMed Web of Science ®Google Scholar
• MalmestromCAnderssonBAHaghighiSLyckeJIL-6 and CCL2 levels in CSF are associated with the clinical course of MS: implications for their possible immunopathogenic rolesJ Neuroimmunol20061751–217618216626811
   PubMed Web of Science ®Google Scholar
• UsluSAkarkarasuZEOzbabalikDLevels of amyloid beta-42, interleukin-6 and tumor necrosis factor-alpha in Alzheimer’s disease and vascular dementiaNeurochem Res20123771554155922437436
   PubMed Web of Science ®Google Scholar